Enanta Pharmaceuticals, Inc. $ENTA Shares Acquired by Trexquant Investment LP

Key Points

• Trexquant Investment LP increased its holdings in Enanta Pharmaceuticals by 113.4% in the first quarter, now owning approximately 1.36% of the company's stock, valued at $1.60 million.
• Enanta Pharmaceuticals reported earnings of ($0.85) per share, exceeding analysts' estimates, and generated revenue of $18.31 million for the quarter.
• Analysts are optimistic about Enanta Pharmaceuticals, with a consensus rating of "Buy" and a price target averaging $22.25 per share.

Trexquant Investment LP increased its holdings in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 113.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 290,059 shares of the biotechnology company's stock after purchasing an additional 154,105 shares during the quarter. Trexquant Investment LP owned approximately 1.36% of Enanta Pharmaceuticals worth $1,601,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Ieq Capital LLC purchased a new stake in Enanta Pharmaceuticals during the first quarter worth approximately $232,000. Jacobs Levy Equity Management Inc. lifted its stake in Enanta Pharmaceuticals by 51.3% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 290,011 shares of the biotechnology company's stock worth $1,668,000 after purchasing an additional 98,285 shares during the last quarter. Millennium Management LLC lifted its stake in Enanta Pharmaceuticals by 22.7% during the fourth quarter. Millennium Management LLC now owns 896,987 shares of the biotechnology company's stock worth $5,158,000 after purchasing an additional 165,692 shares during the last quarter. Nuveen LLC purchased a new stake in Enanta Pharmaceuticals during the first quarter worth approximately $313,000. Finally, Stonepine Capital Management LLC purchased a new stake in Enanta Pharmaceuticals during the fourth quarter worth approximately $1,908,000. Hedge funds and other institutional investors own 94.99% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on ENTA. Wall Street Zen upgraded Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Sunday, June 22nd. JMP Securities boosted their price objective on Enanta Pharmaceuticals from $24.00 to $25.00 and gave the company a "market outperform" rating in a research note on Tuesday, August 12th. HC Wainwright began coverage on Enanta Pharmaceuticals in a research note on Monday, July 28th. They issued a "buy" rating and a $20.00 price objective for the company. Finally, Westpark Capital began coverage on Enanta Pharmaceuticals in a research note on Tuesday, September 2nd. They issued a "buy" rating and a $24.00 price objective for the company. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $22.25.

Enanta Pharmaceuticals Stock Performance

NASDAQ ENTA traded up $0.33 on Thursday, reaching $8.66. The stock had a trading volume of 208,050 shares, compared to its average volume of 148,179. Enanta Pharmaceuticals, Inc. has a 12-month low of $4.09 and a 12-month high of $13.37. The business's 50-day moving average price is $7.85 and its 200 day moving average price is $6.80. The stock has a market cap of $185.15 million, a P/E ratio of -2.00 and a beta of 0.84.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating analysts' consensus estimates of ($1.25) by $0.40. The company had revenue of $18.31 million during the quarter, compared to analysts' expectations of $16.21 million. Enanta Pharmaceuticals had a negative return on equity of 89.02% and a negative net margin of 141.98%. On average, sell-side analysts predict that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.